Device Trial Radar · NCT07932847
Automated Versus Manual Oxygen Titration With the EMILY.AI Device in Hospitalized Patients With Acute Respiratory Failure
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 2027
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Aether Tech S.L.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Hospital Universitario Fundación Jiménez Díaz
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient. Adults admitted to the pulmonology ward of Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain) with acute respiratory failure are randomly assigned to receive oxygen titrated automatically by EMILY.AI or oxygen managed as usual by the nursing team, from randomization until hospital discharge. All participants wear the device; in the usual-care group it only records data. The study compares the time patients stay within their target saturation range, episodes of low and high oxygen, nursing workload, oxygen use, length of stay and patient experience. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.
Conditions
- Acute Respiratory Failure
- Acute-on-chronic Respiratory Failure
- COPD Exacerbation
- Pneumonia
- Interstitial Lung Diseases
Interventions
EMILY.AI closed-loop oxygen titrationDevice
Investigational smart oxygen valve with rule-based algorithm that adjusts oxygen flow to keep SpO2 within a target range.
Manual oxygen titrationOther
Usual care: oxygen flow set and adjusted by the ward nursing team according to standard practice. The EMILY.AI device stays connected in fixed mode, recording signals but not controlling delivery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- EFFICACY - EVALUATION OF THE RATE THE DEVICE MAINTAINS BLOOD OXYGEN SATURATION LEVELSTime frame: From randomization to hospital discharge, up to 30 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.